Tieron / Targeting
Annual report 2026-06-12
Companies › Japanese listed company

エーザイ株式会社 (Eisai Co., Ltd.)

Tokyo Stock Exchange 4523, Pharmaceutical. Supply-chain directory entry built from public EDINET filings, including relationships the company disclosed in its own annual securities report.

COMPANY NAME (JP)
エーザイ株式会社
TICKER
TSE 4523
EDINET CODE
E00939
CORPORATE NUMBER
6010001000001
INDUSTRY
Pharmaceutical (医薬品)
HEAD OFFICE
文京区小石川４丁目６番１０号
DISCLOSED FOOTPRINT
13 sites · 49 subsidiaries

Disclosed major customers

Counterparties Eisai Co., Ltd. named in its own annual securities report. A third-party company named here has Eisai Co., Ltd. in its supply base.

McKesson Corporation10.42% of revenue
“McKesson Corporation86,034アメリカス医薬品事業”
Annual securities report (有価証券報告書), filed 2026-06-12 — EDINET S100YB05
Cencora,Inc.9.13% of revenue
“Cencora,Inc.75,379アメリカス医薬品事業”
Annual securities report (有価証券報告書), filed 2026-06-12 — EDINET S100YB05
(株)メディパルホールディングス7.17% of revenue
“㈱メディパルホールディングス59,202日本医薬品事業”
Annual securities report (有価証券報告書), filed 2026-06-12 — EDINET S100YB05

Disclosed suppliers

Suppliers Eisai Co., Ltd. named in its own annual securities report.

エコナビスタ株式会社
“当社がシステム開発を委託”
Annual securities report (有価証券報告書), filed 2026-06-12 — EDINET S100YB05
WITHIN THE GROUP — Eisai Co., Ltd.’s own consolidated subsidiaries and affiliates (関係会社の状況). Intra-group transfers, not third-party trade.
EAファーマ株式会社
“当社が医薬品の研究開発・製造を受託、医薬品を購入”
Annual securities report (有価証券報告書), filed 2026-06-12 — EDINET S100YB05
Arteryex株式会社
“当社がシステム開発を委託”
Annual securities report (有価証券報告書), filed 2026-06-12 — EDINET S100YB05
テオリア・テクノロジーズ株式会社
“当社がシステム開発を委託”
Annual securities report (有価証券報告書), filed 2026-06-12 — EDINET S100YB05
Eisai Inc.
“当社が医薬品の研究開発・製造を委託、医薬品・原薬を販売”
Annual securities report (有価証券報告書), filed 2026-06-12 — EDINET S100YB05
Eisai Clinical Research Singapore Pte. Ltd.
“当社が医薬品の研究開発を委託”
Annual securities report (有価証券報告書), filed 2026-06-12 — EDINET S100YB05
Eisai Pharmaceuticals India Pvt. Ltd.
“当社が医薬品の研究開発・製造を委託、医薬品・原薬を販売、医薬品・原薬を購入”
Annual securities report (有価証券報告書), filed 2026-06-12 — EDINET S100YB05

Business segments

日本
27.77% of revenue
アメリカス
36.4% of revenue
中国
15.84% of revenue
EMEA
9.88% of revenue
イーストアジア・グローバルサウス
8.34% of revenue
その他事業
1.77% of revenue — 親会社のライセンス収入及び医薬品原料などに係る事業
The filing states a human-rights policy and describes human-rights due diligence: “当社グループでは、2019年3月に「ENW人権方針」を策定しました。国際人権規範に基づく対応は、全社会議体である「ビジネスと人権委員会」が担っています。同委員会にて審議・報告する人権デューデリジェンスにおいて、2025年度は、2024年度に子会社、工場・研究所、一次取引先を対象として実施した人権リスクの高い業種や国・地域を特定するためのアンケート調査結果に基づき、人権リスクの高い取引先や国・地域へのリスク低減施策を実行しました。2026年度以降も人権に負の影響を及ぼす可能性のあるリスクの回避・低”

Sector risk context: supply-chain risk by country and sector.

More Pharmaceutical companies

Takeda Pharmaceutical Company LimitedAnGes, Inc.ASKA Pharmaceutical Holdings CO., Ltd.BrightPath Biotherapeutics Co., Ltd.CanBas Co.,Ltd.Carna Biosciences, Inc.Chiome Bioscience Inc.Chordia Therapeutics,Inc
Screening Eisai Co., Ltd. or mapping suppliers like them? Check any company against sanctions and forced-labor lists, free.Free sanctions check →

Work at Eisai Co., Ltd.? Claim this page to review the data your customers see.

Get sanctions & UFLPA list updates
A short note when the lists change in ways that matter for supply-chain screening. No noise.
Sources: EDINET code list (Financial Services Agency) and the company’s own annual securities report (有価証券報告書) retrieved via EDINET. Disclosed relationships are quoted from the filing and carry its EDINET accession number; extraction is automated and conservative — anything the filing does not state is left out. Tieron does not certify, audit or endorse the company, and this page contains no Tieron risk assessment. Report an issue with this page — corrections referencing the accession number shown above are fastest to verify.
エーザイ株式会社の取引先・主要顧客 — Eisai Co., Ltd. suppliers & customers · Tieron